First steps for Bionomics' anti-anxiety drug
Wednesday, 09 July, 2008
Bionomics [ASX: BNO] has completed GMP synthesis of its anxiety drug candidate BNC210, one of the first stages in its preparation for an IND application from the US FDA.
Pharmaceutical manufacturing contractors Sai Advantium completed the Good Manufacturing Practice (GMP) synthesis, and samples they have produced will be used in the final round of toxicological testing before human trials commence.
To successfully complete GMP synthesis all operational methodologies and procedures involved in creating the drug must be demonstrated to perform their intended function.
BNC210 is part of Bionomics' MultiCore technology platform. The company recently announced a major deal with Merck Serono to develop its potassium ion channel inhibitor kvl.3, and is in clinical trials for its vascular disruption agent BNC105.
'Mini brains' mimic MS myelin damage
The MS organoids give researchers a highly detailed cellular view of myelin destruction...
Fast-aging placentas may contribute to pre-eclampsia
Placentas affected by pre-eclampsia show several signs of accelerated aging, including increased...
BioNTech opens mRNA manufacturing facility at La Trobe
Offering state-subsidised access to researchers and biotech startups, the facility aims to enable...
